Orizal Plus (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, amlodipine, hydrochlorothiazide, the active ingredients in Orizal Plus, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure in adults, often when single‑agent therapy is insufficient. GNH USA supplies Orizal Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Orizal Plus is a combination antihypertensive that acts on several pathways involved in blood pressure regulation. - Hypertension: helps achieve target blood pressure when monotherapy does not provide adequate control. - Hypertensive urgency: used as part of a regimen to lower blood pressure safely under medical supervision. - Cardiovascular risk reduction: contributes to lowering the risk of stroke and heart attack in patients with high blood pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate headache may occur. - Peripheral edema: swelling of the ankles or feet. - Dizziness or light‑headedness, especially after the first doses. - Fatigue: feeling unusually tired. - Flushing: transient warmth or redness of the skin. - Increased urination: due to the diuretic component.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Hyperkalemia: elevated potassium levels that may affect heart rhythm. - Acute kidney injury: sudden decline in renal function. - Angio‑edema: swelling of the face, lips, tongue or throat. - Liver enzyme abnormalities: elevated ALT or AST. - Blood disorders: neutropenia or thrombocytopenia.

When prescribing Orizal Plus, clinicians should consider several safety aspects. - Renal impairment: dose adjustment may be needed in patients with reduced kidney function. - Hepatic impairment: use cautiously in moderate to severe liver disease. - Electrolyte disturbances: monitor potassium and sodium levels regularly. - Pregnancy: avoid use unless clearly needed; discuss risks with a healthcare provider. - Concomitant antihypertensives: risk of additive blood‑pressure lowering effects. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Orizal Plus can interact with a range of medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Aliskiren: combined use with an ARB may increase risk of renal impairment and hyperkalemia. - Potassium‑rich supplements or salts: may cause dangerous hyper‑kalemia. - NSAIDs (high‑dose): can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium levels, requiring serum monitoring. - CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can raise amlodipine concentrations. - Beta‑blockers: additive blood‑pressure lowering effect, monitor for symptomatic hypotension.